Search

Author/Creator Angulo, David A

1. 123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI). (4th December 2021)

Authors:
Pappas, Peter G; Cornely, Oliver; Koehler, Philipp; McCarty, Todd P; Alexander, Barbara D; Miller, Rachel; Vazquez, Jose A; Sanders, John W; Morse, Caryn; Ostrosky-Zeichner, Luis; Krause, Robert; Prattes, Jürgen; Spec, Andrej; Rautemaa-Richardson, Riina; Bazaz, Rohit; Walsh, Thomas J; Marty, Fran...
Journal:
Open forum infectious diseases
Issue:
Volume 8(2021)Supplement 1
Page Start:
S73
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 992. Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI). (4th December 2021)

Authors:
Vazquez, Jose A; Cornely, Oliver; Koehler, Philipp; Rautemaa-Richardson, Riina; Bazaz, Rohit; Marshall Lyon, G; Marty, Francisco M; Gonzalez-Bocco, Isabel H; Miller, Rachel; Walsh, Thomas J; Pappas, Peter; McCarty, Todd P; Sanders, John W; Morse, Caryn; Ostrosky-Zeichner, Luis; Krause, Robert; Pr...
Journal:
Open forum infectious diseases
Issue:
Volume 8(2021)Supplement 1
Page Start:
S586
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). (1st September 2021)

Authors:
Schwebke, Jane R; Sobel, Ryan; Gersten, Janet K; Sussman, Steven A; Lederman, Samuel N; Jacobs, Mark A; Chappell, B Todd; Weinstein, David L; Moffett, Alfred H; Azie, Nkechi E; Angulo, David A; Harriott, Itzel A; Borroto-Esoda, Katyna; Ghannoum, Mahmoud A; Nyirjesy, Paul; Sobel, Jack D
Journal:
Clinical infectious diseases
Issue:
Volume 74:Number 11(2022)
Page Start:
1979
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. 1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI). (31st December 2020)

Authors:
Alexander, Barbara D; Cornely, Oliver; Pappas, Peter; Miller, Rachel; Vazquez, Jose A; Ostrosky-Zeichner, Luis; Spec, Andrej; Rautemaa-Richardson, Riina; Krause, Robert; Thompson III, George R; Morse, Caryn; Sanders, John W; Andes, David; Andes, David; Lyon, George; Marty, Francisco M; Silverman,...
Journal:
Open forum infectious diseases
Issue:
Volume 7:Number 1(2020) Supplement
Page Start:
S642
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗